Evidence map›Paper›PMID 42741862›Full record

ReviewLiver international : official journal of the International Association for the Study of the Liver2026

EuroHePP: The European Toolkit to Strengthen National Responses for the Elimination of Viral Hepatitis in Prisons.

Serena Fondelli, Guglielmo Arzilli, Filipa Alves da Costa, Christian Brixko, Maria Butí, Joaquin Cabezas, Nicola Cocco, Olivia Dawson, Charlotte Deogan, Gabriele Fischer and 14 more

Abstract readReview
In one paragraph

Review in Liver international : official journal of the International Association for the Study of the Liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. EuroHePP: The European Toolkit to Strengthen National Responses for the Elimination of Viral Hepatitis in Prisons.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Serena FondelliDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Guglielmo ArzilliDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.ORCID https://orcid.org/0000-0003-1258-1650
Filipa Alves da CostaResearch Institute for Medicines (iMED), University of Lisbon, Lisbon, Portugal.ORCID https://orcid.org/0000-0003-0562-2514
Christian BrixkoDepartment of Gastroenterology and Hepatology, CHR Citadelle, Liège, Belgium.
Maria ButíLiver Unit, Hospital Universitario Vall D'hebron and CIBER-EHD del Instituto Carlos III, Barcelona, Spain.ORCID https://orcid.org/0009-0002-9620-9812
Joaquin CabezasGastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Marqués de Valdecilla University Hospital, Santander, Spain.ORCID https://orcid.org/0000-0003-0012-484X
Nicola CoccoASST Santi Paolo e Carlo, Milan, Italy.
Olivia DawsonThe International Network on Health and Hepatitis in Substance Users (INHSU), Geneva, Switzerland.
Charlotte DeoganEuropean Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.ORCID https://orcid.org/0000-0002-2082-5419
Gabriele FischerCenter for Public Health, Medical University of Vienna, Vienna, Austria.
Arkadiusz KomorowskiGrüner Kreis Association, Vienna, Austria.ORCID https://orcid.org/0000-0002-1674-4333
Fadi MerouehPH Chef de Service, Service de Soins en Milieu Pénitentiaire, Pôle Santé Publique et Ecologie de la Santé, CHU de Montpellier, Maison D'arrêt de Villeneuve-lès-Maguelone, France.ORCID https://orcid.org/0000-0002-6824-5608
Linda MontanariEuropean Union Drugs Agency (EUDA), Lisbon, Portugal.
Sara MazzilliDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.ORCID https://orcid.org/0000-0002-7989-0661
Éamonn O'MooreNational Health Protection Office, Health Service Executive, Dublin, Ireland.
Roberto RanieriASST Santi Paolo e Carlo, Milan, Italy.
Rafaela RigoniCorrelation, European Harm Reduction Network (C-EHRN), Amsterdam, the Netherlands.ORCID https://orcid.org/0000-0002-8393-4604
Alessio SaponaroGeneral Directorate of Health and Social Policies, Bologna, Italy.
Carole Seguin-DevauxDepartment of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.ORCID https://orcid.org/0000-0003-0636-5222
Ehab SalahPrisons and HIV, United Nations Office on Drugs and Crime (UNODC), Vienna, Austria.
Thomas SeylerEuropean Union Drugs Agency (EUDA), Lisbon, Portugal.
Heino StöverInstitute of Addiction Research, Frankfurt University of Applied Sciences, Frankfurt, Germany.
Lara TavoschiDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.ORCID https://orcid.org/0000-0002-2217-4664
Erika DuffellEuropean Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.

Funding

European Centre for Disease Prevention and Control ECD.14789/2020
6 · The paper itself

Abstract

People living in prison are disproportionately affected by hepatitis B and C, yet access to prevention, testing, and treatment services remains inconsistent across Europe. Addressing this gap is critical to achieving viral hepatitis elimination targets by 2030. EuroHePP is a European toolkit developed to support national responses to viral hepatitis in prison settings. It was created through a structured, multi-stage process involving evidence review, stakeholder consultations, and expert validation. The toolkit provides practical guidance across the full continuum of care, including prevention, testing, treatment, and monitoring, and promotes micro-elimination approaches tailored to prison populations. It emphasises evidence-based interventions such as opt-out testing, decentralised and simplified models of care, harm reduction strategies, and continuity of care after release. By offering adaptable tools and frameworks for policymakers and practitioners, EuroHePP aims to strengthen prison health systems, reduce health inequalities, and accelerate progress towards hepatitis elimination at national and regional levels.

Indexed as

Hepatitis BHepatitis CPrisonersPrisonsEuropeHealth Services for PrisonersHumansbest practicesmicro‐eliminationprison healthtest & treatviral hepatitis

Identifiers

PMID42741862
PMCPMC13575848

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.